AC Immune SA (NASDAQ:ACIU) shares gapped down before the market opened on Tuesday . The stock had previously closed at $7.62, but opened at $7.45. AC Immune shares last traded at $7.37, with a volume of 500 shares.
Several analysts have recently issued reports on ACIU shares. HC Wainwright upped their price target on AC Immune from $11.00 to $16.00 and gave the stock a “buy” rating in a research note on Tuesday, March 30th. Zacks Investment Research raised AC Immune from a “sell” rating to a “hold” rating in a research report on Tuesday, January 26th.
The firm has a fifty day simple moving average of $7.74 and a 200 day simple moving average of $6.12. The stock has a market cap of $504.28 million, a price-to-earnings ratio of -7.79 and a beta of 0.82.
About AC Immune (NASDAQ:ACIU)
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops therapeutic and diagnostic products for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.
See Also: Cost of Debt
Receive News & Ratings for AC Immune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AC Immune and related companies with MarketBeat.com's FREE daily email newsletter.